Pharma major Lupin Ltd. announced that its subsidiary Lupin Pharmaceuticals Inc. had received final approval for its Irbesartan Tablets, 75 mg, 150 mg and 300 mg from the US FDA to market a generic version of Sanofi Aventis US, LLC's Avapro tablets, 75 mg, 150 mg and 300 mg strengths.
Irbesartan is an angiotensin II receptor antagonist and is indicated for the treatment of Hypertension and Nephropathy in Type 2 diabetic patients.
As per IMS MAT data, Avapro tablets had annual sales of around $400.70 million as at the end of June 2012.
A the NSE, Lupin shares are currently trading at Rs.564.85, up 1.67 percent from the previous close.
For comments and feedback contact: editorial@rttnews.com
Business News
December 12, 2025 15:14 ET Central bank decisions dominated the economic news flow this week led by the Federal Reserve. Trade data from the U.S. also gained attention. The Canadian and Swiss central banks also announced their interest rate decisions. Inflation data from China was in focus as the country released the latest consumer price and producer price data.